Mabion signed a deal with Novavax to transfer the manufacturing process and open the way for commercial-scale production of an antigen for a COVID-19 vaccine candidate, Mabion. The Master Service Agreement enables Mabion "with assistance of Novavax, to initiate activities required to transfer the manufacturing process and to establish the feasibility of commercial-scale manufacturing of antigen for Novavax's vaccine candidate" at Mabion's premises. Mabion expects that the transfer of the technology and its verification will be completed in first half 2021.

The deal is effective through December 31, 2023.